Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895639 | 0.88 | HTR2A (0.49) | HTR2AHTR2CTAAR1NR2E1CHRNA7 | |
| SCHEMBL2430644 | 0.80 | BAZ2B (0.47) | HTR2AHTR2CALDH1A1BAZ2BKMT2A | |
| SCHEMBL23875687 | 0.80 | MEN1 (0.44) | KDM4EALDH1A1LMNAMAPTBAZ2B | |
| SCHEMBL31510878 | 0.78 | HTR2A (0.51) | HTR2AHTR2CTAAR1NR2E1CHRNA7 | |
| SCHEMBL31510880 | 0.78 | HTR2A (0.51) | HTR2AHTR2CTAAR1NR2E1CHRNA7 | |
| SCHEMBL6880205 | 0.76 | HSD17B10 (0.52) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL6529663 | 0.75 | HTR2A (0.49) | HTR2AHTR2CTAAR1NR2E1CHRNA7 | |
| SCHEMBL11838605 | 0.73 | LMNA (0.47) | HTR2AHTR2CTAAR1NR2E1CHRNA7 | |
| SCHEMBL31684725 | 0.73 | HTR2A (0.46) | HTR2AHTR2CTAAR1NR2E1CHRNA7 | |
| SCHEMBL4651124 | 0.72 | HTR2A (0.45) | HTR2AHTR2CTAAR1NR2E1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4125874-A1 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335046-A | Lipoxygenase inhibitors | 思研（SRI）国际顾问与咨询公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2021195346-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021195346-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2008065408-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| EP-1848426-A2 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | Hunter-Fleming Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082409-A2 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005033099-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-0242518-B1 | Cycloalkano[1,2-b]indole-sulfonamides | BAYER AG (DE) | 1991-04-10 | — | — | EP | disclosed |
| US-4988820-A | Inhibiting platelet aggregation, anticoagulants, thromboxane a2 antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4965258-A | Anticoagulant; thromboxane a2 antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-23 | — | — | US | disclosed |
| US-4904797-A | REACTING A (BENZENESULFONAMIDOALKYL)CYCLOALKANO(1,2-B)INDOLE WITH ACRYLONITRILE; HYDROLYSIS, HYDROGENATION, REDUCTION | BAYER AKTIENGESELLSCHAFT (DE) | 1990-02-27 | — | — | US | disclosed |
| US-4827032-A | INTERMEDIATES FOR ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-05-02 | — | — | US | disclosed |
| EP-0242518-A1 | Cycloalkano[1,2-b]indole-sulfonamides | BAYER AG (DE) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | HTR2A 826/4885HTR2C 1434/4885TAAR1 2643/4885 |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1012/4885HTR2C 642/4885TAAR1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.